Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Young

Showing results (61-70 of 104) with videos related to

Pageof 11
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|December 11, 2002
Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adultsBenjamin Young, Margaret A Fischl, Helene M Wilson, et al.
HIV Clinical Trials|December 4, 2010
Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trialCalvin Cohen, Edwin Dejesus, Anthony Lamarca, et al.
Journal of the International Association of Providers of AIDS Care|February 5, 2014
Retention in care within 1 year of initial HIV care visit in a multisite US cohort: who's in and who's out?Ellen M Tedaldi, James T Richardson, Rachel Debes, et al.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|December 3, 2004
Fragility fractures in HIV-infected patients: need for better understanding of diagnosis and managementGrace A McComsey, Jeannie S Huang, Ian J Woolley, et al.
HIV Clinical Trials|July 3, 2015
Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudineBenjamin Young, Kathleen E Squires, Karen Tashima, et al.
AIDS (London, England)|August 2, 2008
First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North AmericaBenjamin Young, Kathleen Squires, Parul Patel, et al.
HIV Clinical Trials|November 9, 2012
ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudineKathleen E Squires, Benjamin Young, Edwin DeJesus, et al.
Practical Radiation Oncology|February 18, 2022
A Comparative Study of Patients With Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy Using CyberKnife and Linear Accelerator-Based Volumetric Modulated Arc TherapySaarang R Deshpande, William R Grubb, Michael Kharouta, et al.
The American Journal of Gastroenterology|May 29, 2013
Defining the accuracy of secretin pancreatic function testing in patients with suspected early chronic pancreatitisGyanprakash Ketwaroo, Alphonso Brown, Benjamin Young, et al.
AIDS Research and Treatment|May 22, 2012
Trends in Decline of Antiretroviral Resistance among ARV-Experienced Patients in the HIV Outpatient Study: 1999-2008Kate Buchacz, Rose Baker, Douglas J Ward, et al.
Pageof 11

Showing results (61-70 of 104) with videos related to

Sort By:
Pageof 11
Journal of Acquired Immune Deficiency Syndromes (1999)|December 11, 2002
Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adultsBenjamin Young, Margaret A Fischl, Helene M Wilson, et al.
HIV Clinical Trials|December 4, 2010
Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trialCalvin Cohen, Edwin Dejesus, Anthony Lamarca, et al.
Journal of the International Association of Providers of AIDS Care|February 5, 2014
Retention in care within 1 year of initial HIV care visit in a multisite US cohort: who's in and who's out?Ellen M Tedaldi, James T Richardson, Rachel Debes, et al.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|December 3, 2004
Fragility fractures in HIV-infected patients: need for better understanding of diagnosis and managementGrace A McComsey, Jeannie S Huang, Ian J Woolley, et al.
HIV Clinical Trials|July 3, 2015
Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudineBenjamin Young, Kathleen E Squires, Karen Tashima, et al.
AIDS (London, England)|August 2, 2008
First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North AmericaBenjamin Young, Kathleen Squires, Parul Patel, et al.
HIV Clinical Trials|November 9, 2012
ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudineKathleen E Squires, Benjamin Young, Edwin DeJesus, et al.
Practical Radiation Oncology|February 18, 2022
A Comparative Study of Patients With Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy Using CyberKnife and Linear Accelerator-Based Volumetric Modulated Arc TherapySaarang R Deshpande, William R Grubb, Michael Kharouta, et al.
The American Journal of Gastroenterology|May 29, 2013
Defining the accuracy of secretin pancreatic function testing in patients with suspected early chronic pancreatitisGyanprakash Ketwaroo, Alphonso Brown, Benjamin Young, et al.
AIDS Research and Treatment|May 22, 2012
Trends in Decline of Antiretroviral Resistance among ARV-Experienced Patients in the HIV Outpatient Study: 1999-2008Kate Buchacz, Rose Baker, Douglas J Ward, et al.
Pageof 11